Indomethacin (IMC) as a prophylactic treatment is considered to be ineffective in cluster headache (CH). However, small series suggested the interest of IMC in CH. Some authors support that an IMC test is useful in all trigeminal autonomic cephalalgias. We described clinical features of IMC responders in a retrospective cohort of chronic cluster headache (CCH).
This single-center and retrospective study was conducted in a tertiary care specialist headache center in France. Patients were selected between January 2007 and December 2008. We included all patients fulfilling CCH criteria (ICHD-3-beta). Data were collected from medical records. We recorded all the prescriptions of IMC as a prophylactic treatment. Responders were defined by 50% reduction in attack frequency; complete response was defined by disappearance of the attacks. The non-responders must have received at least 100 mg daily during 7 days.
The study consisted of 324 CCH, 121 female (37%) and 203 males (63%) with an average age at onset of 33.93 (± 14.71) years. Of the patients, 105 were treated with IMC. Thirty patients (29%) were responders. Thirty-four patients (32%) were non-responders. Responding status was undefined for 41 patients (39%). Twelve patients (11%) had a complete response. Responders were composed by 18 women (60%) and 12 men (40%) and had on average 44.89 (± 12.88) years. The minimal effective dose was 86.11 mg daily (± 48.72).
This study shows the interest of IMC in CCH patients. We recommend an IMC test as a third-line treatment in CCH.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808. https://doi.org/10.1177/0333102413485658
(2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1–211. https://doi.org/10.1177/0333102417738202
Fischera M, Marziniak M, Gralow I, Evers S (2008) The incidence and prevalence of cluster headache: a meta-analysis of population-based studies. Cephalalgia 28:614–618. https://doi.org/10.1111/j.1468-2982.2008.01592.x
Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ (2016) Treatment of cluster headache: The American Headache Society Evidence-Based Guidelines: Headache. Headache 56:1093–1106. https://doi.org/10.1111/head.12866
Gabai IJ, Spierings ELH (1989) Prophylactic treatment of cluster headache with verapamil. Headache 29:167–168. https://doi.org/10.1111/j.1526-4610.1989.hed2903167.x
Leone M, D’Amico D, Frediani F et al (2000) Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. Neurology 54:1382–1385. https://doi.org/10.1212/WNL.54.6.1382
May A, Leone M, Áfra J et al (2006) EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 13:1066–1077. https://doi.org/10.1111/j.1468-1331.2006.01566.x
Capobianco D, Dodick D (2006) Diagnosis and treatment of cluster headache. Semin Neurol 26:242–259. https://doi.org/10.1055/s-2006-939925
Bordini EC, Bordini CA, Woldeamanuel YW, Rapoport AM (2016) Indomethacin responsive headaches: exhaustive systematic review with pooled analysis and critical appraisal of 81 published clinical studies: Headache Currents. Headache 56:422–435. https://doi.org/10.1111/head.12771
DosSantos MF, Holanda-Afonso RC, Lima RL, DaSilva AF, Moura-Neto V (2014) The role of the blood-brain barrier in the development and treatment of migraine and other pain disorders. Front Cell Neurosci 8:302
Prakash S, Shah ND, Chavda BV (2010) Cluster headache responsive to indomethacin: case reports and a critical review of the literature. Cephalalgia 30:975–982. https://doi.org/10.1177/0333102409357642
Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9:105–121. https://doi.org/10.1016/j.jpain.2007.09.005
Donnet A, Lanteri-Minet M, Guegan-Massardier E, Mick G, Fabre N, Geraud G, Lucas C, Navez M, Valade D, on behalf of the Societe Francaise d'Etude des Migraines et Cephalees (SFEMC) (2007) Chronic cluster headache: a French clinical descriptive study. J Neurol Neurosurg Psychiatry 78:1354–1358. https://doi.org/10.1136/jnnp.2006.112037
Donnet A, Demarquay G, Ducros A, Geraud G, Giraud P, Guegan-Massardier E, Lucas C, Navez M, Valade D, Lanteri-Minet M, French Headache Society (2014) French guidelines for diagnosis and treatment of cluster headache (French Headache Society). Rev Neurol 170(11):653–670
Manzoni G (1999) Cluster headache and lifestyle: remarks on a population of 374 male patients. Cephalalgia 19:88–94. https://doi.org/10.1046/j.1468-2982.1999.019002088.x
Prakash S, Adroja B (2018) Hemicrania Continua. Ann Indian Acad Neurol 21(Suppl 1):S23–S30
Antonaci F, Sjaastad O (1989) Chronic paroxysmal hemicrania (CPH): a review of the clinical manifestations. Headache 29:648–656. https://doi.org/10.1111/j.1526-4610.1989.hed2910648.x
Aro P, Ronkainen J, Storskrubb T, Vieth M, Engstrand L, Johansson SE, Bolling-Sternevald E, Bolinder G, Alving K, Talley NJ, Agréus L (2010) Use of tobacco products and gastrointestinal morbidity: an endoscopic population-based study (the Kalixanda study). Eur J Epidemiol 25:741–750. https://doi.org/10.1007/s10654-010-9495-8
Garrow D, Delegge MH (2010) Risk factors for gastrointestinal ulcer disease in the US population. Dig Dis Sci 55:66–72. https://doi.org/10.1007/s10620-008-0708-x
Gwee K-A, Goh V, Lima G, Setia S (2018) Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. J Pain Res 11:361–374. https://doi.org/10.2147/JPR.S156938
Freedberg DE, Kim LS, Yang Y-X (2017) The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 152:706–715. https://doi.org/10.1053/j.gastro.2017.01.031
Buzzi M, Formisano R (2003) A patient with cluster headache responsive to indomethacin: any relationship with chronic paroxysmal hemicrania? Cephalalgia 23:401–404. https://doi.org/10.1046/j.1468-2982.2003.00558.x
Geaney DP (1983) Indomethacin-responsive episodic cluster headache. J Neurol Neurosurg Psychiatry 46:860–861. https://doi.org/10.1136/jnnp.46.9.860
Klimek A (1984) Indomethacin-responsive episodic cluster headache. J Neurol Neurosurg Psychiatry 47:1058–1059. https://doi.org/10.1136/jnnp.47.9.1058-a
Prakash S, Dholakia S, Shah K (2008) A patient with chronic cluster headache responsive to high-dose indomethacin: is there an overlap with chronic paroxysmal hemicrania? Cephalalgia 28:778–781. https://doi.org/10.1111/j.1468-2982.2008.01581.x
Lisotto C, Mainardi F, Maggioni F, Zanchin G (2015) O004. Refractory chronic cluster headache responding absolutely to indomethacin. J Headache Pain 16(Suppl 1):A96
Sjaastad O, Dale I (1974) Evidence for a new (?) treatable headache entity. Headache 14(2):105–108
Antonaci F, Costa A, Ghirmai S, Sances G, Sjaastad O, Nappi G (2003) Parenteral indomethacin (the Indotest) in cluster headache. Cephalalgia 23:193–196. https://doi.org/10.1046/j.1468-2982.2003.00495.x
Matharu MS, Goadsby PJ (2002) Trigeminal autonomic cephalgias. J Neurol Neurosurg Psychiatry 72(Suppl 2):ii19–ii26
Wang S-J, Fuh J-L (2010) Can response to indomethacin exclude the diagnosis of cluster headache? Cephalalgia 30:902–903. https://doi.org/10.1177/0333102410362926
The legal approval for the registry has been obtained from the CNIL as an internal study (French National Committee for Informatics and Liberty) under authorization No RGPD/AP-HM 2019-67.
Conflict of interest
Dr. Monta reports no disclosure.
Dr. Redon reports no disclosure.
Dr. Fabre reports no disclosure.
Dr. Donnet reports disclosure with Allergan, Almirall SAS, Astellas, AstraZeneca Pharmaceuticals, Grunenthal, Lilly, MSD, Orkyn, Pfizer, Saint-Jude, Sanofi-Aventis, Teva, Zambon, and Novartis.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Monta, A., Redon, S., Fabre, C. et al. A retrospective observation on 105 patients with chronic cluster headache receiving indomethacin. Neurol Sci (2021). https://doi.org/10.1007/s10072-021-05114-4
- Prophylactic treatment
- Trigeminal autonomic cephalalgia
- Primary headache